Regentis Biomaterials Ltd. RGNT Archives - Page 2 of 2

ThursdayJan 29, 2026 9:00 am

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands U.S. Clinical Site Network for Phase III GelrinC(R) Trial

Regentis Biomaterials (NYSE American: RGNT) announced the expansion of its U.S. clinical site network to support its ongoing pivotal Phase III study of GelrinC(R) for knee cartilage repair and future clinical programs. The expanded network includes leading academic and orthopedic institutions across the United States, including NYU Langone Orthopedic & Sports Medicine, The Ohio State University Wexner Medical Center, University of Cincinnati Medical Center, Loyola Medicine Orthopedic, Tulane University School of Medicine, UNC Orthopedics and Rush University Medical Center, with the company aiming to accelerate patient enrollment, strengthen clinical execution and support future commercialization efforts. To view the full press…

TuesdayJan 20, 2026 9:00 am

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports Long-Term GelrinC(R) Imaging Data Demonstrating Native-Like Cartilage Regeneration

Regentis Biomaterials (NYSE American: RGNT) announced new long-term imaging data from its completed European clinical trial of GelrinC(R), showing regenerated cartilage with internal structural organization closely resembling healthy native hyaline cartilage. Published in the peer-reviewed journal Cartilage, the MRI-based analysis demonstrated progressive tissue maturation over 24 months, with repaired cartilage exhibiting layered architecture comparable to native tissue, supporting GelrinC(R)’s potential to deliver durable cartilage regeneration and long-term joint function. To view the full press release, visit https://ibn.fm/rEL4F About Regentis Biomaterials Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance…

TuesdayJan 06, 2026 9:00 am

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports Long-Term Phase II GelrinC(R) Cartilage Repair Results Published in Cartilage Journal

Regentis Biomaterials (NYSE American: RGNT) today announced publication of long-term follow-up results from its completed Phase II clinical trial of GelrinC(R) in the peer-reviewed journal Cartilage, highlighting durable cartilage regeneration at 24 months. The study reported a mean MOCART score of 88.8 out of 100 across all lesions, with osteochondral lesions achieving a mean score of 94, supporting evidence of near-complete structural repair and maturation toward hyaline-like cartilage based on quantitative MRI assessments. To view the full press release, visit https://ibn.fm/IyWli About Regentis Biomaterials Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that…

MondayJan 05, 2026 12:20 pm

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Secures New U.S. Patent for GelrinC Liquid Formulation

Regentis Biomaterials (NYSE American: RGNT) announced that the U.S. Patent and Trademark Office has issued the company a new patent titled “Organic Solvent Free Compositions Comprising Protein-Polymer Conjugates and Uses Thereof,” covering a liquid, ready-to-use formulation of its lead product, GelrinC(R), as well as improved production processes that eliminate the use of organic solvents. The patent focuses on GelrinC’s liquid formulation, which is designed to simplify surgical procedures and improve patient experience by conforming precisely to cartilage wounds before being cured with UV light to form a temporary elastomeric implant. Regentis said the patent provides protection for GelrinC through 2038…

Site Search

Company Search

Tag: Regentis Biomaterials Ltd. RGNT

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands U.S. Clinical Site Network for Phase III GelrinC(R) Trial

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports Long-Term GelrinC(R) Imaging Data Demonstrating Native-Like Cartilage Regeneration

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports Long-Term Phase II GelrinC(R) Cartilage Repair Results Published in Cartilage Journal

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Secures New U.S. Patent for GelrinC Liquid Formulation

Market Basics

Newsletter Publishers

Public Companies